Our CEO and co-founder, Ronen Eckhouse, recently presented at the Future of Healthcare Investment Forum, hosted by the London Stock Exchange. With a spotlight on our unique portfolio, Mr. Eckhouse emphasized the global need to expand effective stroke care, and how our novel technologies – like #TIGERTRIEVER™️ 13, continue to impact endovascular therapy for the better. Thank you to LSEG (London Stock Exchange Group), Deutsche Numis and Michal Freeman-Shor for sharing your platform to showcase how #RapidMedical is expanding what’s possible in treating stroke. Michal Eran-Shriki
About us
When treating stroke, procedural time and patient safety are critical. Utilizing advanced technology backed by clinical data, Rapid Medical expands what’s possible in neurovascular treatment by offering interventional devices that are fully visible and adjustable in the brain. The result? The unique ability to tailor the procedure to every patient.
- Website
-
http://www.rapid-medical.com/
External link for Rapid Medical
- Industry
- Medical Device
- Company size
- 51-200 employees
- Headquarters
- Yokneam, Israel
- Type
- Privately Held
- Founded
- 2008
- Specialties
- Timeisbrain, Stroke, Neurointervention, Aneurysm, Remodeling, Mechanical Thrombectomy, thrombectomy, interventional, neurovascular, and endovascular
Locations
-
Primary
Carmel building P.O.B. 337
Yokneam, Israel 20692, IL
-
Westendstrasse 21
Frankfurt, Germany 60325, DE
Employees at Rapid Medical
Updates
-
Recent data from the #SUCCESSStudy indicate a favorable safety profile, high effectiveness, and low complication rates with the COMANECI™ embolization assist device. Results reported: ✅ Zero symptomatic thromboembolic events (across all ruptured and unruptured cases) compared to other modalities, including balloons. ✅ 82% mRS 0-2 at <180-day follow-up The only non-occlusive, radially adjustable assist device designed to tackle wide-neck aneurysms – Leave nothing behind with #COMANECI. #hemorrhagicstroke #aneurysm
-
FINAL RESULTS show high occlusion rates of the COMANECI™️ embolization assist device for intracranial aneurysm treatment. The SUCCESS Study assesses the safety and efficacy of COMANECI in the U.S. Data indicates: • 95% (P=0.05) RR I & II at 6 months • Highest occlusion rates across comparable studies 🧠 Data presented by Jason Davies, MD, PhD (principal Study investigator) at #SNIS2024. #COMANECI #hemorrhagicstroke #aneurysm
-
That’s a wrap on a great 2024 SNIS Annual Meeting! From gaining FDA clearance on DRIVEWIRE™️ 24, to presenting exciting new evidence with COMANECI™️ - we’d like to express gratitude to Society of NeuroInterventional Surgery and our partners for your support and enthusiasm throughout the week. It’s because of your collaboration that we’re able to showcase our steadfast commitment to expanding what’s possible in neurointervention. Thank you! Jason Davies, MD, PhD Shahram Majidi Johannes Hensler #RapidMedical #EXPANDWhatsPossible #SNIS2024
-
Rapid Medical reposted this
Rapid Medical has announced the first procedures in the USA with its breakthrough deflectable access platform Drivewire 24, doing so at the ongoing Society of NeuroInterventional Surgery meeting. This milestone follows the recent US FDA clearance of the device. #snis2024 Shahram Majidi Giora Kornblau
-
Rapid Medical reposted this
Rapid Medical’s Drivewire 24 Platform Used in Initial Neurovascular Procedures | #SNIS2024
Rapid Medical’s Drivewire 24 Platform Used in Initial Neurovascular Procedures - Endovascular Today
evtoday.com
-
SNIS Meeting Attendees: On the heels of DRIVEWIRE™ 24’s FDA clearance, join us and Dr. Shahram Majidi outside of the exhibit hall on Bartolin Patio at 2pm for a Grand Prix Event you won’t want to miss! #DW24 at #SNIS24 #ReshapeNavigation
-
LIVE from the 2024 SNIS Annual Meeting, we’re pleased to announce the first cases performed by Dr. Shahram Majidi following FDA clearance of DRIVEWIRE 24 in the US. “DRIVEWIRE addresses a major unmet need in the endovascular space. It transforms access across a range of procedures, from aneurysms to strokes and more. We’re always looking for devices to make procedures faster, safer, less expensive. My first experience with DRIVEWIRE suggests it could do all of these.” Visit booth #109 to learn more & top the Drive to Survive leaderboard! https://lnkd.in/efBKxbVr.
Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution
businesswire.com
-
Our lineup at #SNIS2024 is PAC’d. Visit us at booth #109 for some healthy competition. Test your steering skills at PAC-MAN with a neurovascular twist, and learn more about our other exciting activities throughout the week. See you soon! 🏔 #RapidMedical #DRIVEWIRE
-
SNIS 2024 is around the corner! Join us throughout the week for an exciting pipeline of events you won’t want to miss. - Visit booth #109 to test your steering skills and top the PAC MAN leaderboard - Fuel your passion for fast-paced navigation at the Bartolin Patio on Tuesday with Dr. Shahram Majidi (Register here: https://lnkd.in/e9Xpb9iR) - Reserve time with the crew in our Tech Suite See you in Colorado! 🏔 #RapidMedical #SNIS2024 *COMANECI is not indicated for vasospasm treatment in the U.S. Refer to Instructions for Use (IFU) for full indications & contraindications.